CASTLE ROCK, CO--(Marketwire - August 06, 2010) - AspenBio Pharma, Inc. (NASDAQ: APPY), has been invited to present at the Canaccord Genuity 30th Annual Growth Conference. The conference will be held at the InterContinental Boston on August 10-12, 2010.
Company management is scheduled to present on Thursday, August 12, 2010 at 10:00 a.m. Eastern Time with one-on-one meetings held throughout the day. Management will discuss the company's recent activities surrounding its AppyScore™ Test, the first blood-based test designed as an aid in the diagnosis of human appendicitis.
For more information about the conference or to schedule a one-on-one meeting with the company, contact your Canaccord Adams institutional sales representative. The presentation will be webcast and can be accessed for 90 days following the presentation at the following link: http://www.wsw.com/webcast/canaccord2/appy/
About Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc, offering institutional and corporate clients idea-driven investment banking, merger and acquisition, research, sales and trading services from 11 offices worldwide. Its team of 375 capital markets professionals has industry and transactional expertise in critical sectors of the global economy: Metals and Mining, Energy, Agriculture, Technology, Telecommunications, Financials, Consumer Products, Real Estate, Transportation, Infrastructure, Sustainability, Life Sciences, Support Services and Investment Trusts. More information is available at www.canaccordgenuity.com.
About AspenBio Pharma, Inc.
AspenBio Pharma, Inc. (NASDAQ: APPY) is developing AppyScore -- a novel, blood-based diagnostic test to assist in the difficult challenge of diagnosing appendicitis. AppyScore could play an important role in reducing healthcare costs and patient exposure to harmful radiation from CT scanning. www.aspenbiopharma.com
Investor Relations:
MacDougall Biomedical Communications
Sarah Cavanaugh
781-235-3060
